RBC ups Sartorius, Stedim Biotech as shares underperformance provides an opportunity

Sartorius AG

03/09/2024 10:09

** RBC initiates Sartorius  SATG.DE  with "sector perform"
and Sartorius Stedim Biotech  STDM.PA  with "outperform," as
both stocks' underperformance against peers provides an
opportunity for investors
    ** The shares in the two companies have done worse than
their peers due to guidance downgrades, the brokerage notes
    ** Despite both companies providing a series of guidance
cuts in the past years, RBC expects sales and margins to
outperform consensus forecast from 2025 as they bounce off weak
2023-24 comparatives and normal buying patterns resume
    ** Two analysts out of two covering Sartorius rate it as
"buy"
    ** Out of 13 analysts covering Stedim Biotech, seven rate it
"strong buy"/"buy", 5 "hold" and one "strong sell"  

 (Reporting by Paolo Laudani)
 ((Paolo.laudani@thomsonreuters.com))